(Q48160107)

English

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

author name string

S Belachew

1

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

R Phan-Ba

2

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

E Bartholomé

3

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

V Delvaux

4

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

I Hansen

5

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

P Calay

6

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

K E Hafsi

7

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

G Moonen

8

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

L Tshibanda

9

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

M Vokaer

10

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

publication date

1 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

European Journal of Neurology

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

18

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

2

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

240-245

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

The pharmacovigilance program on natalizumab in Italy: 2 years of experience

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

The search for responsive clinical endpoints in primary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2010.03112.X

21 January 2018

Identifiers

10.1111/J.1468-1331.2010.03112.X

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 February 2018

http://europepmc.org/abstract/MED/20561044

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48160107&oldid=1694257866"